Discovery and Preclinical Studies of (R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an In Vivo Active Potent VEGFR-2 Inhibitor-Reference-Cited by-同舟云学术

Discovery and Preclinical Studies of (R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an In Vivo Active Potent VEGFR-2 Inhibitor

Published:2006-03-16 Issue:7 Volume:49 Page:2143-2146
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Bhide Rajeev S.¹,Cai Zhen-Wei¹,Zhang Yong-Zheng¹,Qian Ligang¹,Wei Donna¹,Barbosa Stephanie¹,Lombardo Louis J.¹,Borzilleri Robert M.¹,Zheng Xiaoping¹,Wu Laurence I.¹,Barrish Joel C.¹,Kim Soong-Hoon¹,Leavitt Kenneth¹,Mathur Arvind¹,Leith Leslie¹,Chao Sam¹,Wautlet Barri¹,Mortillo Steven¹,Jeyaseelan Robert¹,Kukral Daniel¹,Hunt John T.¹,Kamath Amrita¹,Fura Aberra¹,Vyas Viral¹,Marathe Punit¹,D'Arienzo Celia¹,Derbin George¹,Fargnoli Joseph¹

Affiliation:

1. Bristol-Myers Squibb, Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm051106d

Reference19 articles.

1. Angiogenesis in cancer, vascular, rheumatoid and other disease

2. Angiogenesis in cancer and other diseases

3. Tyrosine kinases as targets in cancer therapy – successes and failures